Development of a biomarker mortality risk model in acute respiratory distress syndrome
Oita, Radu C
Camp, Sara M
Miller, Edmund J
Downs, Charles A
Garcia, Joe G N
AffiliationUniv Arizona Hlth Sci, Coll Med
Univ Arizona Hlth Sci, Coll Pharm
MetadataShow full item record
CitationBime, C., Casanova, N., Oita, R.C. et al. Development of a biomarker mortality risk model in acute respiratory distress syndrome. Crit Care 23, 410 (2019). https://doi.org/10.1186/s13054-019-2697-x
RightsCopyright © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractBackground: There is a compelling unmet medical need for biomarker-based models to risk-stratify patients with acute respiratory distress syndrome. Effective stratification would optimize participant selection for clinical trial enrollment by focusing on those most likely to benefit from new interventions. Our objective was to develop a prognostic, biomarker-based model for predicting mortality in adult patients with acute respiratory distress syndrome. Methods: This is a secondary analysis using a cohort of 252 mechanically ventilated subjects with the diagnosis of acute respiratory distress syndrome. Survival to day 7 with both day 0 (first day of presentation) and day 7 sample availability was required. Blood was collected for biomarker measurements at first presentation to the intensive care unit and on the seventh day. Biomarkers included cytokine-chemokines, dual-functioning cytozymes, and vascular injury markers. Logistic regression, latent class analysis, and classification and regression tree analysis were used to identify the plasma biomarkers most predictive of 28-day ARDS mortality. Results: From eight biologically relevant biomarker candidates, six demonstrated an enhanced capacity to predict mortality at day 0. Latent-class analysis identified two biomarker-based phenotypes. Phenotype A exhibited significantly higher plasma levels of angiopoietin-2, macrophage migration inhibitory factor, interleukin-8, interleukin-1 receptor antagonist, interleukin-6, and extracellular nicotinamide phosphoribosyltransferase (eNAMPT) compared to phenotype B. Mortality at 28 days was significantly higher for phenotype A compared to phenotype B (32% vs 19%, p = 0.04). Conclusions: An adult biomarker-based risk model reliably identifies ARDS subjects at risk of death within 28 days of hospitalization.
NoteOpen access journal
VersionFinal published version
- Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsis.
- Authors: Reilly JP, Anderson BJ, Hudock KM, Dunn TG, Kazi A, Tommasini A, Charles D, Shashaty MG, Mikkelsen ME, Christie JD, Meyer NJ
- Issue date: 2016 Jul 18
- Adaptation of a Biomarker-Based Sepsis Mortality Risk Stratification Tool for Pediatric Acute Respiratory Distress Syndrome.
- Authors: Yehya N, Wong HR
- Issue date: 2018 Jan
- Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury.
- Authors: Donnelly TJ, Meade P, Jagels M, Cryer HG, Law MM, Hugli TE, Shoemaker WC, Abraham E
- Issue date: 1994 May
- Interleukin-1 Receptor Antagonist Is Associated With Pediatric Acute Respiratory Distress Syndrome and Worse Outcomes in Children With Acute Respiratory Failure.
- Authors: Dahmer MK, Quasney MW, Sapru A, Gildengorin G, Curley MAQ, Matthay MA, Flori H, BALI and RESTORE Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.
- Issue date: 2018 Oct
- External validation of a biomarker and clinical prediction model for hospital mortality in acute respiratory distress syndrome.
- Authors: Zhao Z, Wickersham N, Kangelaris KN, May AK, Bernard GR, Matthay MA, Calfee CS, Koyama T, Ware LB
- Issue date: 2017 Aug